litlas
Log inCreate account

Michael J. Overman

Active 1995–2026

Also published as
Michael J Overman
187
Papers
27,306
Citations
80
h-index
173
i10-index

Citations

Citations per year for Michael J. Overman1990: 1 citations1996: 5 citations1997: 8 citations1998: 5 citations1999: 3 citations2000: 7 citations2001: 12 citations2002: 8 citations2003: 8 citations2004: 4 citations2005: 1 citations2006: 4 citations2007: 8 citations2008: 3 citations2009: 20 citations2010: 57 citations2011: 52 citations2012: 81 citations2013: 95 citations2014: 72 citations2015: 99 citations2016: 106 citations2017: 203 citations2018: 233 citations2019: 936 citations2020: 1,317 citations2021: 1,561 citations2022: 1,272 citations2023: 1,188 citations2024: 1,643 citations2025: 837 citations2026: 28 citations1991–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,020 citing papers, 24.6% of this breakdownChina: 1,944 citing papers, 15.9% of this breakdownItaly: 790 citing papers, 6.4% of this breakdownUnited Kingdom: 592 citing papers, 4.8% of this breakdownFrance: 556 citing papers, 4.5% of this breakdownGermany: 522 citing papers, 4.3% of this breakdownJapan: 485 citing papers, 4% of this breakdownSpain: 416 citing papers, 3.4% of this breakdownCanada: 307 citing papers, 2.5% of this breakdownNetherlands: 306 citing papers, 2.5% of this breakdownAustralia: 270 citing papers, 2.2% of this breakdownSouth Korea: 245 citing papers, 2% of this breakdown
0%24.6%Other 22.9%

Institutions

Fields

  • Medicine69.5%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology5.4%
  • Engineering1.1%
  • Neuroscience0.6%
  • Computer Science0.5%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers9%
  • Colorectal Cancer Treatments and Studies7.2%
  • Genetic factors in colorectal cancer5.3%
  • Cancer Genomics and Diagnostics4.8%
  • Pancreatic and Hepatic Oncology Research3.3%
  • Colorectal Cancer Surgical Treatments2.6%
  • Other67.8%

Coauthors

All papers

Open in search
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Authors: Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André - The Lancet Oncology 2017 cited by 2,816

  2. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Linda M. Farkas, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna R. Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2021 cited by 1,748

  3. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

    Authors: Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André - Journal of Clinical Oncology 2018 cited by 2,070

  4. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, William R. Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky‐Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2022 cited by 819

  5. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

    Authors: Wenting Liao, Michael J. Overman, Adam T. Boutin, Xiaoying Shang, Di Zhao, Prasenjit Dey, Jiexi Li, Guocan Wang, Zhengdao Lan, Jun Li, Ming‐Jer Tang, Shan Jiang, Xingdi Ma, Peiwen Chen, Riham Katkhuda, Krittiya Korphaisarn, Deepavali Chakravarti, Andrew Chang, Denise J. Spring, Qing Chang, Jianhua Zhang, Dipen M. Maru, Dean Y. Maeda, John A. Zebala, Scott Kopetz, Yin Wang, Ronald A. DePinho - Cancer Cell 2019 cited by 610

  6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

    Authors: Thierry André, Sara Lonardi, Ka Yeung Mark Wong, H.J. Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Michael F. Dixon, Scott Kopetz, Michael J. Overman - Annals of Oncology 2022 cited by 253

  7. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

    Authors: Sangeeta Goswami, Thomas Walle, Andrew Cornish, Sreyashi Basu, Swetha Anandhan, Irina Fernandez, Luis M. Vence, Jorge Blando, Hao Zhao, Shalini S. Yadav, Martina Ott, Ling Yuan Kong, Amy B. Heimberger, John de Groot, Boris Sepesi, Michael J. Overman, Scott Kopetz, James P. Allison, Dana Pe’er, Padmanee Sharma - Nature Medicine 2019 cited by 377

  8. High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

    Authors: Kelvin Allenson, J.J. Soto Castillo, F Anthony San Lucas, Ghislaine Scélo, D.U. Kim, Vincent Bernard, G. Davis, Tripti Kumar, Matthew H. G. Katz, Michael J. Overman, Lenka Foretová, Eleonóra Fabiánová, Ivana Holcátová, Vladimí­r Janout, Funda Meric‐Bernstam, Peter R. C. Gascoyne, Ignacio I. Wistuba, Gauri R. Varadhachary, Paul Brennan, Samir Hanash, D. Li, Anirban Maitra, Héctor M. Álvarez - Annals of Oncology 2017 cited by 487

  9. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

    Authors: Jonathan M. Loree, Seerat Anand, Arvind Dasari, Joseph M. Unger, Anirudh Gothwal, Lee M. Ellis, Gauri Varadhachary, Scott Kopetz, Michael J. Overman, Kanwal Raghav - JAMA Oncology 2019 cited by 569

  10. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

    Authors: Kaysia Ludford, Won Jin Ho, Jane V. Thomas, Kanwal Raghav, M Murphy, Nicole D. Fleming, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar, Arvind Dasari, Sarah M. Shin, Alexei Hernandez, Xuan Yuan, Hongqui Yang, Wai Chin Foo, Wei Qiao, Dipen M. Maru, Scott Kopetz, Michael J. Overman - Journal of Clinical Oncology 2023 cited by 193

  11. Clinical and molecular characterization of early‐onset colorectal cancer

    Authors: Alexandra N. Willauer, Yusha Liu, Allan Andresson Lima Pereira, Michael Lam, Jeffrey S. Morris, Kanwal Raghav, Van K. Morris, David G. Menter, Russell R. Broaddus, Funda Meric‐Bernstam, Andrea Hayes‐Jordan, Winston W. Huh, Michael J. Overman, Scott Kopetz, Jonathan M. Loree - Cancer 2019 cited by 365

  12. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

    Authors: Jorge Blando, Anu Sharma, Maria G. Higa, Hao Zhao, Luis M. Vence, Shalini S. Yadav, Jiseong Kim, Alejandro Martínez Sepúlveda, Michael Sharp, Anirban Maitra, Jennifer A. Wargo, Michael T. Tetzlaff, Russell Broaddus, Matthew H. G. Katz, Gauri R. Varadhachary, Michael J. Overman, Huamin Wang, Cassian Yee, Chantale Bernatchez, Christine A. Iacobuzio–Donahue, Sreyashi Basu, James P. Allison, Padmanee Sharma - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 327

  13. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    Authors: Johanna C. Bendell, Patricia LoRusso, Michael J. Overman, Anne M. Noonan, Dong‐Wan Kim, John H. Strickler, Sang‐We Kim, Stephen Clarke, Thomas J. George, Peter Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha M. Wise‐Draper, Steven Eck, Yu Jiang, Anis A. Khan, Yuling Wu, Philip Martin, Zachary A. Cooper, Nairouz Elgeioushi, Nancy K. Mueller, Rakesh Kumar, Sandip Pravin Patel - Cancer Immunology Immunotherapy 2023 cited by 109

  14. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mohamed A. Adam, George J. Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah E. Hoffe, Steven R. Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, Benjamin D. Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, Frankie Jones - Journal of the National Comprehensive Cancer Network 2024 cited by 308

  15. Survival improvement for patients with metastatic colorectal cancer over twenty years

    Authors: Fadl A. Zeineddine, Mohammad A. Zeineddine, Abdelrahman Yousef, Yue Gu, Saikat Chowdhury, Arvind Dasari, Ryan Huey, Benny Johnson, Bryan K. Kee, Michael S. Lee, Maria Pia Morelli, Van K. Morris, Michael J. Overman, Christine M. Parseghian, Kanwal Raghav, Jason Willis, Robert A. Wolff, Yoshikuni Kawaguchi, Jean‐Nicolas Vauthey, Ryan Sun, Scott Kopetz, John Paul Shen - npj Precision Oncology 2023 cited by 174

  16. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

    Authors: Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon G. Smaglo, Robert A. Wolff, Shubham Pant, Michael S. Lee, Jason Willis, Michael J. Overman, Sudheer Doss, Lynn M. Matrisian, Mark W. Hurd, Rebecca A. Snyder, Matthew H. G. Katz, Huamin Wang, Anirban Maitra, John Paul Shen, Dan Zhao - npj Precision Oncology 2024 cited by 82

  17. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

    Authors: Giovanni Fucà, Romain Cohen, Sara Lonardi, Kohei Shitara, María Elena Elez, Marwan Fakih, Joseph Chao, Samuel J. Klempner, Matthew J. Emmett, Priya Jayachandran, Francesca Bergamo, M. Díez García, Giacomo Mazzoli, Leonardo Provenzano, Raphaël Colle, Magali Svrcek, Margherita Ambrosini, Giovanni Randon, Aakash Tushar Shah, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Keigo Chida, Akihito Kawazoe, Veronica Conca, Giuseppe Curigliano, Francesca Corti, Chiara Cremolini, Michael J. Overman, Thierry André, Filippo Pietrantonio - Journal for ImmunoTherapy of Cancer 2022 cited by 120

  18. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

    Authors: Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna R. Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2020 cited by 500

  19. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

    Authors: Christine M. Parseghian, Jonathan M. Loree, Van K. Morris, X Liu, Katherine Clifton, Stefania Napolitano, Jason T. Henry, Allan Andresson Lima Pereira, Eduardo Vilar, Benny Johnson, Bryan K. Kee, Kanwal Raghav, Arvind Dasari, Jingjing Wu, Naveen Garg, Victoria M. Raymond, Kimberly C. Banks, AmirAli Talasaz, Richard B. Lanman, John H. Strickler, David S. Hong, Ryan B. Corcoran, Michael J. Overman, Scott Kopetz - Annals of Oncology 2018 cited by 240

  20. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer

    Authors: Angela N. Bartley, Anne M. Mills, Eric Q. Konnick, Michael J. Overman, Christina B. Ventura, Lesley Souter, Carol Colasacco, Zsofia K. Stadler, Sarah E. Kerr, Brooke E. Howitt, Heather Hampel, Sarah F. Adams, Wenora Johnson, Cristina Magi‐Galluzzi, Antonia R. Sepulveda, Russell R. Broaddus - Archives of Pathology & Laboratory Medicine 2022 cited by 143

  21. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

    Authors: Praveen Vikas, Hans Messersmith, Carolyn C. Compton, Lynette M. Sholl, Russell R. Broaddus, Anjee Davis, Maria Del Pilar Estevez-Diz, Rohan Garje, Panagiotis A. Konstantinopoulos, Aliza Leiser, Anne M. Mills, Barbara M. Norquist, Michael J. Overman, Davendra Sohal, Richard Turkington, Tyler Johnson - Journal of Clinical Oncology 2023 cited by 110

  22. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer

    Authors: Kanwal Pratap Singh Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric‐Bernstam, David G. Menter, Krittiya Korphaisarn, B. Kee, Andrea Murányi, Shalini Singh, Mark J. Routbort, Ken Chen, Kenna Shaw, Riham Katkhuda, Kandavel Shanmugam, Dipen M. Maru, Marwan Fakih, Scott Kopetz - JCO Precision Oncology 2019 cited by 132

  23. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer

    Authors: Rahul A. Sheth, Ravi Murthy, David S. Hong, Sapna P. Patel, Michael J. Overman, Adi Diab, Patrick Hwu, Alda L. Tam - JAMA Network Open 2020 cited by 114

  24. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

    Authors: Benny Johnson, Cara Haymaker, Edwin R. Parra, Luisa M. Solis Soto, Xuemei Wang, Jane V. Thomas, Arvind Dasari, Van K. Morris, Kanwal Raghav, Eduardo Vilar, Bryan K. Kee, Cathy Eng, Christine M. Parseghian, Robert A. Wolff, Younghee Lee, Daniele Lorenzini, Caddie Laberiano-Fernández, Anuj Verma, Wenhua Lang, Ignacio I. Wistuba, P. Andrew Futreal, Scott Kopetz, Michael J. Overman - Journal for ImmunoTherapy of Cancer 2022 cited by 52